The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi Group21 - 22 October 2019, Boston, USA.
With a massive growth within the HPAPI market, manufacturers cannot afford to be complacent in terms of staff training, utilization of approved technology and blueprint accident plans. Straying away from the correct procedures can have a massive affect on your business and industry.

At the inaugural HPAPI USA conference, these issues will be discussed and give delegates the opportunity to hear from industry experts who will share their experiences and arm attendees with the safety strategies to implement into their organization.

Ayasha Ovals from Taro Pharmaceuticals will provide a keynote address on Day One of the conference, where she will give insights into emergency procedures for HPAPI disasters and how to manage an accident, including long term cost savings, managing risk, fail-safe procedure and forward planning.

Industrial hygiene and potent compound containment will be discussed by Joseph Grill, former Associate Director from Purdue Pharma, where he will share insights on common pitfalls in industrial hygiene, flexible containment and the potential of hastening R&D.

Sakari Consultants, President & Principle, Patricia Weidemanwill focus on training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management. She will also look at technological innovations for containment and transfer technologies, ensuring staff are sufficiently trained and ensure they understand the equipment they are utilising.

The programme with full speaker line-up is available to download at www.hpapi-usa.com

Plus, two HPAPI USA Post Conference Workshops will take place in Boston on October 23rd:

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics hosted byDr Janet Gould, Principal Toxicologist, SafeBridge Consultants and Charlyn Reihamn, Principle Occupational Health Consultant,SafeBridge Consultants

Workshop B: How to sell your containment project to management: financial justification for containment solutions hosted by DrDavid Eherts, Vice President Global EHS, Allergan Inc

For those interested, an early bird saving of $300 is available for conference tickets booked before Friday 28th June. Register online at www.hpapi-usa.com

Sponsoredby BSP Pharmaceuticals, LONZA, Minakem, SafeBridge Consultants

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 This email address is being protected from spambots. You need JavaScript enabled to view it.

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...